Clinical Trials Browser

Phase 1/2 × Lymphoma, T-Cell, Peripheral × 1 year × Clear all

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT04390737 2026-01-30

Evaluate the Safety and Clinical Activity of HH2853

Phase 1/2 Recruiting

254 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Lymphoma, T-Cell, Peripheral

NCT06909877 2026-01-30

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

100 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02264613 2026-01-13

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Completed

142 enrolled 30 charts

Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

56 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT07093710 2025-12-31

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

101 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

250 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT07288814 2025-12-17

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Phase 1/2 Not yet recruiting

43 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT06421948 2025-12-05

Linperlisib Combined With Chidamide in Patients With PTCL

Phase 1/2 Recruiting

134 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02223208 2025-12-02

FIL_PTCL13

Phase 1/2 Active not recruiting

89 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Phase 1/2 Not yet recruiting

48 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06035497 2025-05-14

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Phase 1/2 Recruiting

85 enrolled

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT04105010 2025-04-04

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Phase 1/2 Completed

171 enrolled 23 charts

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Clinical Trials

RELATIVITY-069

Evaluate the Safety and Clinical Activity of HH2853

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

TOUCH

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Linperlisib Combined With Chidamide in Patients With PTCL

FIL_PTCL13

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)